Acute Ischemic Stroke

Neurology
21
Pipeline Programs
23
Companies
50
Clinical Trials
6 recruiting
4
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
2
6
1
4
6
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
3100%
+ 31 programs with unclassified modality

On Market (4)

Approved therapies currently available

U
ENOXAPARIN SODIUMApproved
enoxaparin sodium
Unknown Company
intravenous, subcutaneous2022
U
ENOXAPARIN SODIUM (PRESERVATIVE FREE)Approved
enoxaparin sodium
Unknown Company
subcutaneous2023
Sanofi
LOVENOXApproved
enoxaparin sodium
Sanofi
intravenous, subcutaneous1993
Sanofi
LOVENOX (PRESERVATIVE FREE)Approved
enoxaparin sodium
Sanofi
subcutaneous1993

Competitive Landscape

21 companies ranked by most advanced pipeline stage

Route 92 Medical
Route 92 MedicalCA - San Mateo
3 programs
1
Route 92 Medical Reperfusion SystemsPhase 41 trial
Route 92 Medical Reperfusion SystemN/A1 trial
ThrombectomyN/A1 trial
Active Trials
NCT05018650Completed250Est. May 2024
NCT05429658Completed66Est. Feb 2022
NCT07436156Recruiting500Est. Nov 2029
Sanofi
SanofiPARIS, France
1 program
1
LOVENOX(Enoxaparin sodium)Phase 45 trials
Active Trials
NCT00721760Completed1,003Est. Oct 2009
NCT00714597Terminated421Est. Mar 2009
NCT00697099Completed2,326Est. Jun 2009
+2 more trials
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
2 programs
2
TenecteplasePhase 31 trial
TenecteplasePhase 31 trial
Active Trials
NCT07253181Recruiting572Est. Mar 2028
NCT07361302Recruiting1,325Est. Oct 2027
P
PharmazzIndia - Greater Noida
1 program
1
Drug: Normal SalinePhase 31 trial
Active Trials
NCT05691244Recruiting514Est. Nov 2026
Qilu Pharmaceutical
Qilu PharmaceuticalChina - Jinan
1 program
1
MonosialogangliosidePhase 31 trial
Active Trials
NCT06742216CompletedEst. Aug 2023
Angel Pharmaceuticals
Angel PharmaceuticalsChina - Zhejiang
1 program
1
Uric AcidPhase 2/31 trial
Active Trials
NCT00860366CompletedEst. Oct 2013
Heidelberg Pharma
Heidelberg PharmaGermany - Ladenburg
2 programs
1
Medical oxygenPhase 21 trial
Endovascular recanalisationN/A1 trial
Active Trials
NCT02126085Completed150Est. May 2016
NCT03500939Terminated223Est. Aug 2022
Biogen
BiogenCAMBRIDGE, MA
2 programs
2
natalizumabPhase 2Monoclonal Antibody5 trials
natalizumabPhase 2Monoclonal Antibody1 trial
Active Trials
NCT05418010Recruiting40Est. Oct 2027
NCT05265728Terminated21Est. May 2024
NCT02133924Completed76Est. Nov 2021
+3 more trials
AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
ElezanumabPhase 2Monoclonal Antibody4 trials
Active Trials
NCT04278235Available
NCT04309474Completed121Est. Dec 2024
NCT04295538Completed60Est. Jan 2026
+1 more trials
DiaMedica Therapeutics
DiaMedica TherapeuticsMINNEAPOLIS, MN
1 program
1
Recombinant human tissue kallikreinPhase 21 trial
Active Trials
NCT03290560CompletedEst. Jan 2020
Astellas
AstellasChina - Shenyang
1 program
1
YM872Phase 22 trials
Active Trials
NCT00044070CompletedEst. Jan 2003
NCT00044057CompletedEst. Jan 2003
DS
Daiichi SankyoChina - Shanghai
3 programs
1
1
DS-1040bPhase 1/21 trial
DS-1040bPhase 13 trials
DS1040bN/A1 trial
Active Trials
NCT03198715Completed42Est. Jan 2020
NCT02647307Completed48Est. Jun 2016
NCT02560688Completed22Est. Mar 2016
+2 more trials
Grifols
GrifolsNEW YORK, NY
1 program
1
PlasminPhase 1/21 trial
Active Trials
NCT01014975CompletedEst. Feb 2014
Pfizer
PfizerNEW YORK, NY
1 program
1
ILS-920Phase 11 trial
Active Trials
NCT00827190Completed16Est. Jul 2009
RapidPulse
RapidPulseFL - Miami
4 programs
RapidPulseTM Aspiration SystemN/A1 trial
RapidPulseTM Aspiration SystemN/A1 trial
RapidPulseTM Aspiration SystemN/A1 trial
RapidPulseTM Aspiration SystemN/A1 trial
Active Trials
NCT05122637CompletedEst. Dec 2022
NCT05577351CompletedEst. Jun 2023
NCT05899036CompletedEst. Oct 2024
+1 more trials
Penumbra
PenumbraALAMEDA, CA
3 programs
Endovascular TherapyN/A1 trial
Mechanical ThrombectomyN/A1 trial
Penumbra SystemN/A1 trial
Active Trials
NCT05029414Active Not RecruitingEst. Jun 2025
NCT05437055Completed216Est. Dec 2024
NCT00963989Completed146Est. Sep 2016
Bayer
BayerLEVERKUSEN, Germany
2 programs
Berlin Atrial Fibrillation RegistryN/A1 trial
Rivaroxaban Acute Stroke Safety StudyN/A1 trial
Active Trials
NCT02306824Completed1,080Est. Nov 2020
NCT02279940Completed50
BALT
BALTCA - Irvine
1 program
CATCHVIEWN/A1 trial
Active Trials
NCT03754296Withdrawn0Est. Mar 2020
Abbott
AbbottABBOTT PARK, IL
1 program
Detection of Muscle Loss in Acute Stroke Patients Who Need Enteral Nutrition (MASS)N/A1 trial
Active Trials
NCT03825419Completed125Est. Nov 2021
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
Rev-01N/A1 trial
Active Trials
NCT01895634Completed49Est. Nov 2014
Siemens Healthineers
Siemens HealthineersGermany - Forchheim
1 program
Standard workflowN/A1 trial
Active Trials
NCT05644938UnknownEst. Dec 2023

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
Route 92 MedicalRoute 92 Medical Reperfusion Systems
Biogennatalizumab
Biogennatalizumab
SanofiEnoxaparin sodium
SanofiEnoxaparin sodium
SanofiEnoxaparin sodium
SanofiEnoxaparin sodium
Boehringer IngelheimTenecteplase
Boehringer IngelheimTenecteplase
PharmazzDrug: Normal Saline
Biogennatalizumab
Qilu PharmaceuticalMonosialoganglioside
SanofiEnoxaparin sodium
SanofiEnoxaparin sodium
SanofiEnoxaparin sodium

Showing 15 of 49 trials with date data

Clinical Trials (50)

Total enrollment: 44,395 patients across 50 trials

NCT07436156Route 92 MedicalRoute 92 Medical Reperfusion Systems

SUMMIT RISE Study of Acute Ischemic Stroke Patients

Start: Feb 2026Est. completion: Nov 2029500 patients
Phase 4Recruiting

Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants

Start: Nov 2014Est. completion: May 2016111 patients
Phase 4Terminated

Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies

Start: Sep 2014Est. completion: May 201647 patients
Phase 4Terminated
NCT00232271SanofiEnoxaparin sodium

The Effect of Enoxaparin Sodium on the Incidence of Deep Vein Thrombosis Following Electrophysiology Studies and Radiofrequency Ablation.

Start: Aug 2005Est. completion: Feb 201135 patients
Phase 4Terminated
NCT00077805SanofiEnoxaparin sodium

PREVAIL: PREvention of VTE After Acute Ischemic Stroke With LMWH Enoxaparin ( - VTE: Venous Thromboembolism - LMWH: Low Molecular Weight Heparin)

Start: Aug 2003
Phase 4Completed
NCT00077818SanofiEnoxaparin sodium

Enoxaparin Versus Unfractionated Heparin in Subjects Who Present to the Emergency Department With Acute Coronary Syndrome (RESCUE)

Start: Jun 2002
Phase 4Completed
NCT00077753SanofiEnoxaparin sodium

EXCLAIM:Extended Prophylaxis for Venous ThromboEmbolism (VTE) in Acutely Ill Medical Patients With Prolonged Immobilization

Start: Feb 2002Est. completion: Feb 20074,726 patients
Phase 4Completed

A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well

Start: Feb 2026Est. completion: Oct 20271,325 patients
Phase 3Recruiting

Tenecteplase Before Interhospital Transfer for EVT in Acute Anterior Circulation LVO at 4.5-24 Hours

Start: Jan 2026Est. completion: Mar 2028572 patients
Phase 3Recruiting
NCT05691244PharmazzDrug: Normal Saline

Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke

Start: Jul 2025Est. completion: Nov 2026514 patients
Phase 3Recruiting

A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis

Start: Apr 2022Est. completion: May 202421 patients
Phase 3Terminated
NCT06742216Qilu PharmaceuticalMonosialoganglioside

Monosialoganglioside in Acute Ischemic Stroke: a Randomized, Blinded and Multicenter Confirmatory Study

Start: Nov 2020Est. completion: Aug 2023
Phase 3Completed
NCT00721760SanofiEnoxaparin sodium

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Hip Fracture Surgery

Start: Jul 2008Est. completion: Oct 20091,003 patients
Phase 3Completed
NCT00714597SanofiEnoxaparin sodium

Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients With Restricted Mobility

Start: Jul 2008Est. completion: Mar 2009421 patients
Phase 3Terminated
NCT00697099SanofiEnoxaparin sodium

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery

Start: Jun 2008Est. completion: Jun 20092,326 patients
Phase 3Completed
NCT00679588SanofiEnoxaparin sodium

Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major Abdominal Surgery

Start: Apr 2008Est. completion: Aug 20104,413 patients
Phase 3Completed
NCT00349180SanofiEnoxaparin sodium

Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)

Start: Jun 2006156 patients
Phase 3Completed

Natalizumab Re-Initiation of Dosing

Start: Mar 2006Est. completion: Feb 2008404 patients
Phase 3Completed
NCT00077792SanofiEnoxaparin sodium

Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment Thrombolysis in Myocardial Infarction - Study 25 (ExTRACT-TIMI25)

Start: Oct 2002Est. completion: Dec 200620,506 patients
Phase 3Completed

Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease

Start: Dec 2001Est. completion: Sep 2003905 patients
Phase 3Completed

Efficacy Study of Combined Treatment With Uric Acid and rtPA in Acute Ischemic Stroke

Start: Jun 2011Est. completion: Oct 2013
Phase 2/3Completed
NCT00077844SanofiEnoxaparin sodium

Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention (PCI) Patients, an International Randomized Evaluation (STEEPLE)

Start: Jan 2004Est. completion: Sep 20053,532 patients
Phase 2/3Completed

Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)

Start: Dec 2022Est. completion: Oct 202740 patients
Phase 2Recruiting

A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke

Start: Nov 2020Est. completion: Dec 2024121 patients
Phase 2Completed

Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)

Start: Sep 2020Est. completion: Jan 202660 patients
Phase 2Completed

Penumbral Rescue by Normobaric O2 Administration in Patients With Ischemic Stroke and Target Mismatch ProFile

Start: Aug 2019Est. completion: Aug 2022223 patients
Phase 2Terminated

A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis

Start: Feb 2019Est. completion: Aug 2021123 patients
Phase 2Completed
NCT03290560DiaMedica TherapeuticsRecombinant human tissue kallikrein

Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke

Start: Jan 2018Est. completion: Jan 2020
Phase 2Completed

Multicenter Study Of Natalizumab Plus Standard Steroid Treatment For High Risk Acute Graft-Versus-Host Disease

Start: Aug 2016Est. completion: Nov 202176 patients
Phase 2Completed

Safety and Efficacy of Intravenous Natalizumab in Acute Ischemic Stroke

Start: Jul 2016Est. completion: Nov 2017277 patients
Phase 2Completed

Natalizumab Subcutaneous Immunogenicity and Safety Study

Start: Dec 2014Est. completion: Jun 20152 patients
Phase 2Terminated

Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke

Start: Jan 2014Est. completion: Apr 2015161 patients
Phase 2Completed

Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)

Start: Aug 2011Est. completion: Oct 2014290 patients
Phase 2Completed

Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis

Start: Oct 2010Est. completion: Dec 201497 patients
Phase 2Completed

Natalizumab Treatment of Progressive Multiple Sclerosis

Start: Mar 2010Est. completion: Jan 201224 patients
Phase 2Completed
NCT00331838SanofiEnoxaparin sodium

Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery

Start: May 2006Est. completion: Jun 2007705 patients
Phase 2Completed

Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving Methotrexate

Start: May 2004299 patients
Phase 2Terminated

Natalizumab in Combination With Glatiramer Acetate (GA) in Patients With Relapsing-Remitting Multiple Sclerosis

Start: Jun 2003Est. completion: Mar 2004110 patients
Phase 2Completed

Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's Disease

Start: Apr 2002Est. completion: Jul 200360 patients
Phase 2Completed

A Study to Evaluate the Effects of YM872 on Stroke Lesion Volume in Acute Stroke Patients

Start: Dec 2000Est. completion: Jan 2003
Phase 2Completed

A Study to Evaluate the Effects of YM872 on Brain Function and Disability When Administered in Combination With Alteplase (Tissue Plasminogen Activator)

Start: Dec 2000Est. completion: Jan 2003
Phase 2Completed

Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of DS-1040b in Subjects With Acute Ischemic Stroke

Start: Sep 2015Est. completion: Aug 2019106 patients
Phase 1/2Completed

A Safety and Dose Finding Study of Plasmin (Human) Administered Into the Middle Cerebral Artery of Stroke Patients

Start: Nov 2009Est. completion: Feb 2014
Phase 1/2Completed

Study of the Effects of Ethnicity on the Pharmacokinetics, Pharmacodynamics and Safety of DS-1040b

Start: Feb 2016Est. completion: Jun 201648 patients
Phase 1Completed

Phase 1 Study to Evaluate the Safety and Tolerability of DS-1040b IV Infusion With Clopidogrel in Healthy Subjects

Start: Dec 2015Est. completion: Mar 201622 patients
Phase 1Completed

DS1040b/Aspirin Drug/Drug Interaction Study

Start: Jan 2014Est. completion: Feb 201418 patients
Phase 1Completed

Study Evaluating Single Ascending Doses Of ILS-920

Start: Feb 2009Est. completion: Jul 200916 patients
Phase 1Completed

Expanded Access to Elezanumab

N/AAvailable
NCT06029491RapidPulseRapidPulseTM Aspiration System

The Pivotal Study of RapidPulseTM Aspiration System

Start: Mar 2025Est. completion: Apr 2027
N/ARecruiting
NCT05899036RapidPulseRapidPulseTM Aspiration System

Early Feasibility Study of RapidPulseTM Aspiration System for Patients With Acute Ischemic Stroke

Start: Mar 2024Est. completion: Oct 2024
N/ACompleted

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

4 late-stage (Phase 3) programs — potential near-term approvals
6 actively recruiting trials targeting 44,395 patients
23 companies competing in this space